

Cohort-based surveillance of SARS-CoV2 transmission mirrors infection rates at the population level – a one-year longitudinal study

Christine Klein, MD^{1#*}, Max Borsche, MD^{1#}, Alexander Balck, MD^{1,2#}, Bandik Föh, MD^{3,4#}, Johann Rahmöller, MD^{3,5}, Elke Peters⁶, Jan Knickmann, PhD⁷, Miranda Lane⁷, Eva-Juliane Vollstedt, MD¹, Susanne A. Elsner, PhD⁶, Nadja Käding, MD⁸, Susanne Hauswaldt, MD⁸, Tanja Lange, MD⁹, Jennifer E. Hundt, DVM¹⁰, Alexander Mischnik, MD¹¹, Stefan Niemann, PhD¹², Florian Maurer, MD¹², Susanne Homolka, PhD¹², Laura Paulowski, PhD¹², Jan Kramer, MD^{7,13}, Christoph Twesten, MD¹⁴, Christian Sina, MD³, Gabriele Gillessen-Kaesbach, MD¹⁵, Hauke Busch, PhD¹⁶, Marc Ehlers, PhD³, Stefan Taube, PhD⁷, Jan Rupp, MD^{8*}, Alexander Katalinic, MD^{6*}

¹Institute of Neurogenetics, University of Lübeck and University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany

²Department of Neurology, University of Lübeck, Lübeck, Germany

³Institute of Nutritional Medicine, University of Lübeck, Lübeck, Germany

⁴Medical Department I, University Hospital Schleswig-Holstein, Lübeck, Germany

⁵Department of Anesthesiology and Intensive Care, University Medical Center Schleswig-Holstein, Lübeck, Germany

⁶Institute of Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany

⁷Institute of Virology and Cell Biology, University of Lübeck, Lübeck, Germany

⁸Department of Infectious Diseases and Microbiology, University of Lübeck and University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany

⁹Department of Rheumatology & Clinical Immunology, University of Lübeck and University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany

¹⁰Department of Dermatology, University of Lübeck and University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

¹¹Health Protection Authority, Lübeck, Germany

¹²Research Center Borstel, Leibniz Lung Center, Borstel, Germany

¹³LADR Laboratory Group Dr. Kramer & Colleagues, Geesthacht, Germany

¹⁴Perfood GmbH, Lübeck, Germany

¹⁵University of Lübeck, Lübeck, Germany

¹⁶Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany

*correspondence to:

Prof. Christine Klein, MD

Institute of Neurogenetics

University of Lübeck and University Hospital Schleswig Holstein, Campus Lübeck

Ratzeburger Allee 160; D-23538 Lübeck

Phone: +49-451-3101-8200

E-Mail: christine.klein@neuro.uni-luebeck.de

Prof. Alexander Katalinic, MD

Institute of Social Medicine and Epidemiology

University of Lübeck and University Hospital Schleswig Holstein, Campus Lübeck

Ratzeburger Allee 160; D-23538 Lübeck

Phone: +49-451-500-51200

E-Mail: alexander.katalinic@uni-luebeck.de

Prof. Jan Rupp, MD

Department of Infectiology and Microbiology

University of Lübeck and University Hospital Schleswig Holstein, Campus Lübeck

Ratzeburger Allee 160; D-23538 Lübeck

Phone: +49-451-500-45300

E-Mail: jan.rupp@uni-luebeck.de

#shared first authorship

Short title: One-year cohort-based surveillance of SARS-CoV2

Key words: SARS-CoV-2; COVID-19; longitudinal study; low-prevalence area

Title: 115 characters; Abstract: 250 words; Main text: 3,360 words; Tables: 1; Figures: 4; References:

21

Abstract

Background

More than one year into the COVID-19 pandemic, important data gaps remain on longitudinal prevalence of SARS-CoV-2 infection at the population level and in defined risk groups, efficacy of specific lockdown measures, and on (cost-)effective surveillance.

Methods

The ELISA (Lübeck Longitudinal Investigation of SARS-CoV-2 Infection) study invited adult inhabitants (n~300,000) from the Lübeck area (Northern Germany) and enrolled 3051 participants (~1%); 1929 population-matched and 1645 with high-exposure based on profession. The one-year study period (03/2020-02/2021) covered massive influx of tourism in the summer, rise of infection rates in the fall/winter 2020/2021, and two lockdowns. Participants were screened seven times for SARS-CoV-2 infection using PCR and antibody testing and monitored with an app-based questionnaire (n~91,000).

Results

Cohort (56% female; mean age: 45.6 years) retention was 75%-98%; 92 persons (3.5%) were antibody- and/or PCR-positive. Seropositivity was almost 2-fold higher in men and increased risk detected in several high-exposure groups (highest for nurses, followed by police, army, firemen, and students). In May 2020, 92% of the infections were missed by PCR testing; by February 2021, only 29% remained undiagnosed. "Contact to COVID-19-affected" was the most relevant risk factor. Other factors, such as frequent use of public transportation, shopping, close contacts at work, and extensive tourism in the summer did not impact infection rates.

Conclusions

We i) provide a model for effective, regional surveillance; ii) identify infection risk factors informing public health measures; iii) demonstrate that easing of lockdown measures appears safe at times of low prevalence in the presence of continuous monitoring.

Introduction

In their - still - timely Perspective entitled ‘Defining the epidemiology of COVID-19 – Studies needed’ published in March 2020 in this Journal, Lipsitch and colleagues called upon the scientific community to carry out studies that provide the evidence required for controlling an epidemic.¹ Over the past year, the epidemic has grown to become a pandemic with >150 million confirmed cases and >3 million deceased COVID-19 patients across the globe.² Although research activities on all aspects of SARS-CoV-2 infection and COVID-19 are unprecedented in speed and scope, resulting in >140,000 articles listed in PubMed in the past 16 months, information currently remains scarce on i) prevalence and dynamics of SARS-CoV-2 infection and longitudinal antibody profiles at the population level and in defined risk groups; ii) efficacy of and compliance with different lockdown measures; and iii) (cost-)effective surveillance approaches that allow representative monitoring of the population including early detection of asymptomatic cases and new outbreaks especially in low-prevalence regions.

Population-based studies, such as the one undertaken in the Icelandic population at the beginning of the pandemic, are typically cross-sectional or cover short time intervals.³ In the Italian municipality of Vo, initial testing of 86% of the population revealed a prevalence of SARS-CoV-2 infection of 2.6%, which dropped to 1.2% after a two-week strict lockdown and revealed 42% of asymptomatic infections.⁴ However, the population’s behavior was not systematically monitored and long-term follow-up data are presently unavailable, as is the case for ongoing longitudinal studies for which only study protocols have been published to date.⁵ Of further note, effects of containment measures are rarely assessed directly but rather modeled⁶ and unlikely to be widely generalizable from one geographic and/or cultural setting to another.

We here report the results of a 1-year, longitudinal, prospective cohort study surveilling ~3000 people (~1% of the population living in our catchment area), which included ~20,000 virus PCR and anti-SARS-CoV-2 spike protein (S1) IgG antibody tests and ~90,000 detailed App-based data sets on symptoms, mobility, pandemic-related behavior, and quality of life.

Methods

Study oversight and design

The ELISA (Lübeck Longitudinal Investigation of SARS-CoV-2 Infection) study was approved by the ethics committee of the University of Lübeck (Az. 20-150) and sponsored by the Federal Ministry for Education and Research (BMBF), the State of Schleswig-Holstein, the University of Lübeck, and by a crowd-funding campaign organized by the University of Lübeck. Participants were invited to take part in the study through announcements in the local press, posters and leaflets, and by advertisement on the official homepage of the City of Lübeck by its mayor. Detailed study information was provided on ELISA's website (<https://elisa-luebeck.de>), by telephone counseling, and in newsletters. Within two weeks in April 2020, 7,303 adult inhabitants of the greater Lübeck area (approx. 300,000 inhabitants) downloaded the dedicated ELISA App with its initial questionnaire. Of these 7303 participants, 3474 were selected for subsequent SARS-CoV-2 testing, whereas all 7303 were invited to fill out the study questionnaire, covering retrospectively also the period from the beginning of the pandemic in March 2020. Of the 3474 selected persons, 2145 individuals matched by age and sex distribution of the study region were randomly drawn to comprise a population-based group. An additional 1329 individuals were selected to enrich a potential high-exposure group based on profession requiring intense and/or frequent contact with other people, such as health care personnel or police officers (**Figure 1.A**). 3051 persons (88%) came to the study center for initial screening and form the ELISA cohort used for further analyses. All cohort members were invited to the study center seven times between early May 2020 to February 2021. This time period included the end of the first lockdown, massive influx of tourism in the summer period, rise of infection rates in the fall/winter 2020/2021, and the second lockdown. All participants were tested for current or previous SARS-CoV-2 infection using nucleic-acid and anti-spike protein (extracellular S1 part) IgG antibody testing with support of a mobile app-based questionnaire, electronic scheduling and result reporting system. A timeline outlining the milestones and concurrent lockdown measures is depicted in **Figure 2. A**.

Study setting

The greater Lübeck area (300,000 inhabitants) is located on the Baltic Sea coast (**Figure S1**) and a magnet for national and international tourism with >2 million overnight stays in 2019 and an average of >50,000 visitors per day with high season in the summer. Until the second wave of the COVID-19 pandemic in Germany, Lübeck was a low-prevalence area (**Figure 2.B**), although it belongs to the greater metropolitan area of Hamburg, a COVID-19 high-prevalence area. While there was practically no tourism during the two lockdowns in March and December, tourism in the summer and fall (June to October 2020) reached or even surpassed the already high influx of tourists in previous years (**Figure 2.C**). These numbers were supported by mobility data from Google, which noted a significant increase in the use of public transportation relative to all of Germany (p-value <10⁻³⁰, moderated F-test) including other German touristic hotspots, particularly Bavaria (**Figure 2.D**). Travel to workplaces, however, remained similar across all the states and Germany (p-value=0.39; moderated F-test) (**Figure 2.E**).

Detection of SARS-CoV-2-Infections

Trained study personnel (doctors and medical students) performed deep nasal and oropharyngeal swabs and combined them into a single tube for each participant prior to RNA isolation. SARS-CoV-2 quantitative Real-Time PCR (RT-PCR) from dry swabs was performed at the National Reference Center for Mycobacteria at the Research Center Borstel (RCB), Leibniz Lung Center⁷ and the University Hospital Schleswig-Holstein (UKSH), Lübeck, using validated PCR platforms. External supporting sites included the LADR Central Lab Dr. Kramer & Colleagues, Geesthacht and Centogene GmbH, Rostock, using accredited SARS-CoV-2 diagnostic pipelines. Briefly, dry swabs were suspended within 24 hours and processed for nucleic acid extraction using QIAamp[®] Viral RNA Kits (Qiagen, Hilden) or the NucliSens[®] easyMAG[™] platform (Biomérieux), according to the manufacturers' instructions. Nucleic acids were eluted and quantitative RT-PCR was performed according to the manufacturers' instructions using the first WHO Emergency Use⁸ listed In vitro diagnostics coronavirus (COVID-19)

genesig® Real-Time PCR assay (Primerdesign™ Ltd), or the iTaq Universal Probes 1-Step kit (Bio-Rad, Feldkirchen) in conjunction with primers and probes from the SARS-CoV-2 (2019-nCoV) CDC qPCR Probe Assay (IDT, Leuven, Belgium). All in-house PCR assays were validated and passed the interlaboratory quality control (INSTAND, Düsseldorf).

For antibody testing, a venous blood sample was drawn. The EUROIMMUN SARS-CoV-2 S1 IgG (#EI 2606-9601-2 G) ELISA was performed according to the manufacturer's instructions for examination time-points 1, 6, and 7 and partially for time-points 3 and 5 for participants with increased anti-S1 IgG antibody titers at time-point 1. Participants with an antibody titer against the S1 antigen of >1.1 (compared to an anti-S1 IgG-positive reference serum provided by the manufacturer in the ELISA detection system) were defined as anti-S1 IgG antibody-positive. Following a conservative approach regarding the risk of false-positive findings and in line with independent evaluations of this assay,⁹ values between 0.8 and 1.1, which are considered borderline according to the manufacturer, were not included in further analyses. All persons with antibody-positive results without actual information on PCR-testing were contacted by telephone to inquire about potential external PCR-positive test results obtained in between study visits. All participants were informed about their PCR and antibody results via a secure electronic study portal. Vaccination of medical personnel began at the end of December 2020 and thus was relevant for the last examination time-point.

App data

Participants were initially asked to answer a baseline questionnaire including demographic data, level of education, symptoms of infection and allergies, profession, travel, activities of daily living (such as shopping or attending events), details of adherence to lockdown and later precautionary measures (social distancing, home office, personal protective measures, decreased mobility), contact with children, and self-reported results of previous SARS-CoV-2 tests (since the beginning of the pandemic) (Supplement – Questionnaires). Participants were asked to repeat this App-based questionnaire running on mobile devices (using an adaptation of the MillionFriends App by Perfood GmbH

(<https://perfood.de/>) every three days until September 2020, corresponding to examination time-points 1-5. In December 2020 and February 2021, participants were asked to fill out the questionnaire only once (time-points 6 and 7).

Statistical analysis

Data of the ELISA study was stored in a central study database and was pseudonymized for subsequent analyses. We used descriptive statistics (frequency tables and cross tabulations) to characterize the ELISA cohort and its subgroups. The prevalence of PCR- or antibody-positive participants was estimated using the Kaplan-Meier method. Persons who did not attend all study visits were censored after their last visit. We also censored all participants who underwent vaccination before visiting the study center at the last examination time-point (n=269, 8.8% of the cohort). To explore the potential impact of symptoms on PCR- or antibody-positive results, we identified for each participant whether a symptom was positive for at least one time-point during the study period and marked this person as symptom-positive. For analyzing behavior and quality of life, we calculated a mean behavior score over time for each variable and participant (e.g., mean frequency of eating out). Next, we dichotomized the variables at the median into low/high levels of behavior. We used Cox-Regression to estimate hazard ratios for symptom and behavior variables and calculated 95% confidence intervals for prevalence and risk estimates. Differences in temporal trends were analyzed by a moderated F-test on a regression spline curve with 5 degrees of freedom.

Results

Study cohort

The ELISA cohort (n=3051) comprises 56% females and 44% males; the mean age is 45.6 years (SD 15.2 range: 18-79 years). Demographic details of the entire cohort and its two overlapping subgroups (The high-exposure sub group includes 523 persons from the population-matched subgroup), and results of the SARS-CoV-2 PCR and antibody testing are summarized in **Table 1**.

Acute PCR-confirmed SARS-CoV-2 infections and anti-S1 IgG levels

Participation rates were 75% to 98% across all seven examination time-points (**Figure 1.A**). Two study participants reported PCR-confirmed SARS-CoV-2 infection before the first examination. The number of individuals with reported PCR-confirmed SARS-CoV-2 infection in the Study App increased over the course of the study and reached n=40 in February 2021. In addition, three and two individuals were tested positive at the study center in November/December 2020 and February 2021, respectively. Twenty-four participants were seropositive at baseline (anti-S1 IgG levels >1.1); 61 developed anti-S1 IgG levels above the cut-off over the study course (**Figure 3.A**). In relative numbers, the seropositivity rate within the study cohort increased slightly until September 2020, then more pronounced in November/December 2020, and even more so in February 2021 (**Figure 3.B**). The frequency of PCR-confirmed SARS-CoV-2 infections showed a similar tendency, however, with a peak in November/December 2020 (**Figure 3.B**). Stability of the anti-S1 IgG antibody titer over time in individuals with anti-S1 IgG levels >1.1 on time-point 1 is depicted in **Figure S3**. Within the one-year observation period, 92 persons (3.5%) were antibody-positive (n=85) and/or had a positive PCR test result (n=45) (**Table S2**). Thirty-nine of the 45 PCR-positive persons had an additional antibody test after having tested positive before; 37 (95%) of them were positive for Anti S1 IgG antibodies. The five and six anti-S1 IgG antibody-positive samples at time-point 3 and 5, respectively, had shown increased antibody titers already at baseline, however, with ratios <1.1. Prevalence of seropositivity in the ELISA cohort was almost 2-fold higher in men than in women (4.6% vs. 2.4%) and increased risk was detected in several high-exposure groups. The highest prevalence of 11.2% was observed for nurses (geriatric and nursing care), followed by other medical staff (e.g., residents), police, army, firemen, and students. Assuming that antibody-positive findings represent the true prevalence, about 92% of all infections were missed by PCR testing in May 2020 (n=22/24). By February 2021, only 29% of the new antibody positive cases (11/38) remained undiagnosed.

Analysis of risk stratification, behavior, quality of life and correlation with antibody profiles

The development of symptoms, behavior, and quality of life during the pandemic (**Figure 4.A**) were assessed from April 2020 to February 2021 and are based on self-reports from 3051 study participants in a total of 90,923 electronic questionnaires obtained through the Study App.

Frequencies of infection symptoms rose between lockdown periods and dropped during the second lockdown. Behaviors were either stable (e.g., use of face masks), increased in frequency between lockdowns in relation to alleviation of the lockdown measures (e.g., eating out or attending events) and dropped again sharply during the second lockdown. The dip in frequency of many behaviors in the summer, as well as the drop of children in school to 0% are related to the 6-week summer vacation period and indicative of summer travel of ELISA Study participants. Contact to COVID-19 patients increased during the second lockdown. Quality of life remained stable for all included parameters with the exception of a moderate drop in social integration during the second lockdown period (**Figure 4.A**). The occurrence of three of the self-reported symptoms for infections (at least once in the one-year observation period) was associated with anti-S1 IgG antibody/PCR positivity: loss of smell/taste (HR 2.86 [95%CI 1.71 to 4.78]), shortness of breath (HR 2.22 [95%CI 1.45 to 3.41]), and chills (HR 2.12 [95%CI 1.25 to 3.60]) (**Figure 4.B, Table S3**). Of note, predictive value of these symptoms was low (e.g., only 18 out of 183 (10%) persons with impairment of smell or taste were infected). Analysis of different behaviors revealed “contact to persons with COVID-19” as the most relevant factor for testing positive (HR 2.59 [95%CI 1.67 to 4.03]) (**Figure 4.B**). Other factors, such as frequent use of public transportation, shopping or close contacts at work did not impact infection rates. Mobility data revealed an association between the decrease of the use of public recreation areas - likely indicating reduced outdoor activities - and the increase of SARS-CoV-2 infections in the study area (**Figure S3**).

Discussion

The ELISA Study is the first to provide longitudinal data throughout the SARS-CoV-2 pandemic on a prospectively followed, population-based cohort in an area of overall low prevalence. Compared to

the earlier point-of-care test approaches,¹⁰ it is further unique for its comprehensive design of seven rounds of PCR and antibody testing, combined with close digital tool-based recording of symptoms, behavior, and well-being. There is a critical need to identify specific groups and situations associated with an increased risk for SARS-CoV-2 infection,¹¹ as such knowledge is urgently needed to inform choice and duration of preventive measures. Currently, only modeling¹² and cross-sectional studies with relatively small sample sizes are available.¹³ Moreover, in most countries, including Germany, no structured population-based measures of high methodological quality have been implemented as yet, and data assessed by the health authorities remain to be of insufficient quality, even one year after the onset of the pandemic. The high retention rate and acceptance among our study participants over a one-year period confirm feasibility of large-scale, long-term surveillance studies. As monitoring of 1% of the local population successfully mirrored reported infection rates of the region with acceptable precision, our study design may serve as an efficient and cost-effective model for future virus surveillance programs in other cities or regions.

Despite a large influx of tourism and mobility in the summer, as well as an unexpected rise of SARS-CoV-2 infection rates in the previously low-incidence study region in the fall and winter of 2020, overall antibody seropositivity of 3.5% remained low across all study time-points. It is also profoundly lower compared to high-prevalence areas such as Tirschenreuth in Germany,¹⁴ Val Gardena in Italy,¹⁵ or New York City in the United States.¹⁶ Of note, none of these recent studies included a comparable longitudinal and prospective design. Seropositivity in the Lübeck study area reached only about one twentieth of the ~70% required for herd immunity further stressing the vulnerability of the vast majority of the population and the pivotal role of vaccination.

As expected, the initially low infection rate in the ELISA Cohort rose in accordance with reported infection rates for the region. Perhaps the most important finding is the dramatic decrease of the proportion of undetected SARS-CoV-2 infections from 92% in Mai 2020 to 29% in February 2021. While this observation is a clear reflection of the vastly increased testing efforts, the initial high rate of

underreporting also challenges the accuracy of reported prevalence rates at the beginning of the pandemic when the true incidence may have been up to 11 times higher than the official figures.

Several COVID-19-linked symptoms, infection risk-associated behaviors, and higher occupational exposure in health care personnel,¹⁷ police, fire-brigade, and students were confirmed or newly identified as plausible risk factors for SARS-CoV-2 infection. In contrast, other potential risk factors did not seem to contribute to the risk of infection, such as use of public transportation, eating out or having a child in school. In keeping with these observations, extensive use of public transportation during the peak tourist season in Lübeck, well exceeding its use in other parts of Germany, did not lead to any increase in infection rates or infection hotspots. Another important area of discussion relates to schools as a relevant driver of the pandemic. In our study, only 2/160 teachers were antibody-positive after one year, confirming results from a prospective study conducted in primary schools in England.¹⁸ Other studies have used mobility networks to inform reopening¹⁹ and identified selected ethnicities²⁰ and individuals with close household contacts²¹ to be at higher risk of infection.

Despite the massive influx of tourism from Germany into the Lübeck area in the summer of 2020, even overcompensating the almost complete lack of tourists from abroad and in parallel with an almost complete ease of lockdown restrictions and high mobility of the study population itself, we did not observe an increase in infection rates among our study participants. Thus, tourism and ease of restrictions appeared to be safe during this 5-month period of low general prevalence and high level of outdoor activities in the summer. Notably, all of these findings have to be interpreted in the context of (partial) lockdown periods, continuous, closely observed hygiene measures, and the overall low prevalence in our study area. However, despite limited interpretability of our results by the small size of individual subgroups and low predictive values, we do provide important data to inform the ongoing discussion of lockdown measures, as well as of prioritization of vaccination of specific at-risk groups. The sharp rise in infection rates in late 2020 raises the important question as to whether we could have predicted the 'second wave'. Not surprisingly, contact with infected individuals was the strongest sole risk factor for SARS-CoV-2 infection in our study and we hypothesize a fast rise in diffuse

transmission, as soon as incidences surpass a critical threshold and quickly reach exponential growth when no (new) lockdown measures are promptly imposed. While there were no changes of behavior or emerging differences in our high-exposure group that might have heralded an imminent 'second wave', testing intervals in the fall and winter spanned two months due to restricted funding. However, we noted a strong anti-correlation between rise in the number of infections in Lübeck and the use of public recreation areas from Google mobility data ($r=-0.85$, testing 35 days from Sept 1st to Nov 15th; $r=-0.83$ Germany-wide for the same time period). This finding is likely indicative of more indoor activities that may have fostered closer contact with infected individuals.

Strengths of our study include its comprehensive and longitudinal design, the quality of virus and antibody testing, exceptionally high cohort retention, and the dynamic nature of the study region in terms of tourism, mobility and sudden change from a low- to a high-prevalence region. Limitations are the relatively wide-spread examination time-points in the fall/winter 2020/2021 and overrepresentation of highly motivated study participants with a slightly above-average education level.

In conclusion, we i) provide a model for effective, regional surveillance of the pandemic; ii) underscore the role of vaccination especially in low-prevalence regions remaining far from herd immunity; iii) identify plausible infection risk factors informing public health measures; iv) demonstrate that easing of lockdown measures appears safe even over several months at times of very low prevalence rates; v) underline that continuous monitoring of infections and immediate and consequent imposition of appropriate measures are mandatory to contain virus spread in case of an incipient rise in infection rates.

Acknowledgments

We are very grateful to the participants for taking part in our study over the entire one-year period, strengthening our results through the high cohort retention rate. Moreover, we would like to thank Isabell Rosin, Katja Herrmann-Malzahn, Christoph Westenberger, and Aiham Alabid for excellent assistance in creating the website and organizing the study, and Karolin Ratalics, Nina Janzen and Torsten Schröder for technical support with the study app. Finally, we thank Emily L. Martin, Vera von Kopylow, Inga Künsting, Anne S. Lixenfeld, and Julia Giese for their great help in performing the antibody analysis.

Funding

The study was funded by the Federal Ministry of Education and Research (BMBF) within the B-FAST program, by the State of Schleswig-Holstein, and crowdfunding from the citizens of Lübeck organized by the University of Lübeck.

References

1. Lipsitch M, Swerdlow DL, Finelli L. Defining the Epidemiology of Covid-19 - Studies Needed. *N Engl J Med* 2020;382(13):1194–6.
2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis* 2020;20(5):533–4.
3. Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic Population. *N Engl J Med* 2020;382(24):2302–15.
4. Lavezzo E, Franchin E, Ciavarella C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature* 2020;584(7821):425–9.
5. Radon K, Saathoff E, Pritsch M, et al. Protocol of a population-based prospective COVID-19 cohort study Munich, Germany (KoCo19). *BMC Public Health* 2020;20(1):1036.
6. Gatto M, Bertuzzob E, Maria L, Miccolid S, Carraroe L. Spread and dynamics of the COVID-19 epidemic in Italy: effects of emergency containment measures. *PNAS. Proc Natl Acad Sci USA* 2020;117(19):10484–91.
7. Homolka S, Paulowski L, Andres S, et al. Two Pandemics, One Challenge-Leveraging Molecular Test Capacity of Tuberculosis Laboratories for Rapid COVID-19 Case-Finding. *Emerg Infect Dis* 2020;26(11):2549–54.
8. World Health Organization. WHO Emergency Use Listing for In vitro diagnostics (IVDs) Detecting SARS-CoV-2 Nucleic Acid. https://www.who.int/diagnostics_laboratory/200908_eul_sars_cov2_product_list.pdf, assessed May 9, 2021.
9. Beavis KG, Matushek SM, Abeleda APF, et al. Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies. *J Clin Virol* 2020;129:104468.

10. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *Lancet* 2020;396(10250):535–44.
11. Semenza JC, Adlhoch C, Baka A, et al. COVID-19 research priorities for non-pharmaceutical public health and social measures. *Epidemiol Infect* 2021;149:e87.
12. Leung K, Wu JT, Liu D, Leung GM. First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment. *Lancet* 2020;395(10233):1382–93.
13. Tenforde MW, Fisher KA, Patel MM. Identifying COVID-19 Risk Through Observational Studies to Inform Control Measures. *JAMA* 2021;325(14):1464–5.
14. Wagner R, Peterhoff D, Beileke S, et al. Estimates and determinants of SARS-CoV-2 seroprevalence and infection fatality ratio using latent class analysis: the population-based Tirschenreuth study in the hardest-hit German county in spring 2020. *medRxiv* 2021;2021.03.29.21254343.
15. Melotti R, Scaggiante F, Falciani M, et al. Prevalence and determinants of serum antibodies to SARS-CoV-2 in the general population of the Gardena Valley. *medRxiv* 2021;2021.03.19.21253883.
16. Pathela P, Crawley A, Weiss D, et al. Seroprevalence of SARS-CoV-2 following the largest initial epidemic wave in the United States: Findings from New York City, May 13-July 21, 2020. *J Infect Dis* 2021, online ahead of print.
17. Iversen, K., Bundgaard, H., Hasselbalch, R. B., et al. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study. *Lancet. Infectious Diseases* 2020;20(12):1401–1408.
18. Ladhani SN, Baawuah F, Beckmann J, et al. SARS-CoV-2 infection and transmission in primary schools in England in June-December, 2020 (sKIDs): an active, prospective surveillance study. *Lancet Child Adolesc Health* 2021, online ahead of print.

19. Chang S, Pierson E, Koh PW, et al. Mobility network models of COVID-19 explain inequities and inform reopening. *Nature* 2021;589(7840):82–7.
20. Mathur R, Rentsch CT, Morton CE, et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. *Lancet* 2021, online ahead of print.
21. Metlay JP, Haas JS, Soltoff AE, Armstrong KA. Household Transmission of SARS-CoV-2. *JAMA Netw Open* 2021;4(2):e210304–4.

Table

Table 1. Study participants and group-wise results of antibody screening					
		Value		AB- or PCR positive prevalence	
		N	(%)	N	% (CI)
ELISA cohort (total)		3051	(100)	92	3.5 (2.8 to 4.3)
Gender	Women	1710	(56)	45	3.1 (2.2 to 4.1)
	Men	1341	(44)	47	4.1 (2.9 to 5.2)
Age	18-39	1199	(39)	36	3.8 (2.5 to 5.0)
	40-59	1164	(38)	31	3.1 (2.0 to 4.1)
	60-79	688	(23)	25	3.9 (2.4 to 5.4)
Flagged as high-contact person		1645	(54)	48	3.6 (2.6 to 4.6)
Education	low	916	(30)	33	4.4 (2.9 to 5.8)
	high	2127	(70)	58	3.1 (2.3 to 3.9)
Population sub cohort		1929	(100)	60	3.6 (2.7 to 4.5)
Gender	Women	1046	(54)	18	2.4 (1.3 to 3.5)
	Men	883	(46)	42	4.6 (3.2 to 6.0)
Age	18-39	669	(35)	19	3.6 (2.0 to 5.2)
	40-59	656	(34)	16	2.7 (1.4 to 4.0)
	60-79	604	(31)	25	4.5 (2.7 to 6.2)
Flagged as high contact person		523	(27)	16	3.9 (2.0 to 5.9)
Education	low	550	(29)	21	4.5 (2.6 to 6.4)
	high	1375	(71)	39	3.2 (2.2 to 4.2)
High contact sub groups		1645	(100)	48	3.6 (2.6 to 4.6)
Police, army, fire brigade		90	(5)	4	4.5 (0.2 to 8.9)
Nurses		236	(14)	13	11.2 (4.5 to 17.8)
Other medical staff		41	(2)	2	4.8 (0.0 to 11.2)
Sales and distribution		186	(11)	5	3.2 (0.4 to 6.0)
Daycare teachers		131	(8)	5	4.2 (0.6 to 7.9)
School teachers		160	(10)	2	1.5 (0.0 to 3.6)
Students		255	(16)	10	4.6 (1.8 to 7.5)
Physician - outpatient practice		122	(7)	1	0.9 (0.0 to 2.7)
Physician - hospital		142	(9)	3	2.7 (0.0 to 5.8)
Other		282	(17)	3	1.4 (0.0 to 3.0)

Note: There is an overlap between the population sub cohort and the high contact groups. 523 persons of population group with high contacts are also included in the high contact groups.

Figures




Figure 1. Study design and numbers of PCR- and anti-S1 IgG antibody (AB)-positive individuals. The ELISA cohort was prospectively followed from May 6th, 2020 – February 27th, 2021.

